the non-obese Diabetic (noD) mouse model for type i diabetes also develops some features of Sjögren's syndrome (SS). Since the source of the mice and the environment exert a strong influence on diabetes, this study investigated SS development in noD mice obtained from two vendors. female noD mice from the Jackson Laboratory (JAX) and taconic Biosciences were monitored for blood glucose and pilocarpine-induced salivation. The gut microbiome was analyzed by 16S rRNA sequencing of stool DnA. At euthanasia, serum cytokines and sialoadenitis severity were evaluated. the onset of diabetes was significantly accelerated in JAX mice compared to Taconic mice. Although the gut microbiome between the two groups was distinct, both groups developed sialoadenitis. there was no correlation between the severity of sialoadenitis and reduced saliva production. instead, salivary gland dysfunction was associated with hyperglycemia and elevation of serum IL1β, IL16, and CXCL13. Our data suggest that inflammatory pathways linked with hyperglycemia are confounding factors for salivary gland dysfunction in female noD mice, and might not be representative of the mechanisms operative in SS patients. considering that noD mice have been used to test numerous experimental therapies for SS, caution needs to be exerted before advancing these therapeutics for human trials.
Results
Salivary gland dysfunction is associated with hyperglycemia. A previous report in the literature showed a higher incidence of diabetes in the NOD/ShiLtJ (JAX) mice compared to NOD/MrkTac (Taconic) mice 4 . Our data also showed that by 20 weeks of age, 80% (12/15) of JAX mice were hyperglycemic with blood glucose >250 mg/dL, compared to 42% (8/19) of Taconic mice (see Supplementary Fig. S1 ). The 16S rRNA sequencing of stool DNA samples revealed a dramatically distinct gut microbiome composition between the two groups of mice, thereby highlighting the role of gut microbiota in diabetes development in NOD mouse (See Supplementary Fig. S2 ).
To evaluate salivary gland function, we measured pilocarpine-induced saliva production at different time points. In JAX mice, there was a significant (p = 0.0092) drop in mean saliva produced at 16 weeks of age ( Fig. 1a) . In contrast, Taconic mice showed a modest but significant (p = 0.0415) drop at 18-20 weeks of age (Fig. 1b ). The analysis of saliva production in JAX and Taconic mice showed that a majority of the mice showing lower saliva amounts had elevated blood glucose. Hence, saliva amounts between hyperglycemic (blood glucose >250 mg/dL) and normoglycemic (blood glucose <250 mg/dL) mice were compared. At 18-20 weeks of age, mice with high blood glucose had significantly lower mean amount of saliva (67%, p < 0.0001) ( Fig. 1c ).
In our established method of saliva collection 12 , to account for any pilocarpine dosage effects, the amount of saliva produced is normalized by the total body weight of the mouse. This is an important consideration since the mouse body weights are liable to change with age over an extended period of time (see Supplementary  Fig. S3 ). However, the saliva data analyzed without the weight normalization also showed the same results (See Supplementary Fig. S3 ). Further, regardless of the method used, the functional loss in the hyperglycemic mice was identical (67%, p < 0.0001).
Salivary gland inflammation does not correlate with hyperglycemia. The presence of lymphocytic
foci in salivary glands is a characteristic feature of SS, which is recapitulated by the NOD mouse model 2 . To accurately quantify the extent of inflammation in the salivary glands, we determined the area fraction of the salivary gland section occupied by lymphocytic infiltrates (Fig. 2a ). The submandibular glands from the Taconic mice had significantly (p = 0.0289) higher inflammation than the JAX mice ( Fig. 2b ). However, the severity of salivary gland inflammation between mice with or without hyperglycemia was not significantly different ( Fig. 2c ). In addition, regardless of the mouse source, the severity of inflammation in salivary glands did not correlate with salivary gland dysfunction ( Fig. 2d ). Instead, the mice showed a trend in increased saliva production with higher % area of inflammation. An analysis including only normoglycemic mice (n = 11) showed a similar trend of higher saliva production correlating with increased inflammation. Again, this correlation failed to reach statistical significance (r = 0.48, p = 0.1506).
Hyperglycemic NOD mice have distinct circulating cytokine profile. To investigate mechanisms
responsible for salivary gland dysfunction, a 33-plex assay was used to measure serum cytokine levels in mice with high and low blood glucose ( Fig. 3 and see Supplementary Fig. S4 ). Hyperglycemic mice showed significantly higher levels of IL1β (p = 0.0101), IL16 (p = 0.004), and CXCL13 (p = 0.005), and significantly lower levels of CCL4 (p = 0.008), IL10 (p = 0.0134), and IFNγ (p = 0.023). All three elevated cytokines in the hyperglycemic mice The amount of saliva was compared between mice with blood glucose levels less than or greater than 250 mg/dL. Statistical significance was determined by two-tailed unpaired t-test at 95% confidence interval and a p < 0.05 was considered significant.
www.nature.com/scientificreports www.nature.com/scientificreports/ showed a significant inverse correlation between cytokine levels and the amount of saliva produced. In contrast, cytokines elevated in normoglycemic mice showed a modest but statistically significant direct correlation (CCL4: r = 0.5308, p = 0.0075, IL10: r = 0.5216, p = 0.0075 and IFNγ r = 0.4024, p = 0.0461) with saliva production.
Differential gene expression in the submandibular glands of hyperglycemic mice. To investigate
the effects of hyperglycemia and elevated cytokine levels on salivary gland gene expression, submandibular glands from Taconic mice (six normoglycemic and six hyperglycemic) were used to analyze RNA expression by employing the nCounter mouse Immunology panel ( Fig. 4 ). Although several genes activated downstream of innate immune pathways showed upregulation, only Nfkbia, Irak2 and C4a met the cut-off for statistical significance.
Discussion
Systemic autoimmunity, exocrine gland inflammation, reduced tear, and saliva production are hallmarks of SS. Thus, any therapy that aims to treat SS needs to reverse not only the course of an ongoing autoimmune response but also restore the fluid secretion ability of the exocrine glands. The NOD mice develop autoantibodies, severe inflammation in the submandibular glands, and salivary gland dysfunction and have been widely used in SS www.nature.com/scientificreports www.nature.com/scientificreports/ research 2 . However, with increasing age, a substantial proportion of female NOD mice develop hyperglycemia limiting the time frame over which SS studies can be performed. The hyperglycemic mice become moribund and have to be removed from the analyses to avoid potentially confounding effects of hyperglycemia on SS phenotype 11 . The consequence is a considerable limitation in the number of mice evaluated and a skewed representation of data from mice retained in the experiment. In this study, using NOD mice from two distinct commercial sources, we show that salivary gland dysfunction is strongly associated with the onset of hyperglycemia and the systemic elevation of pro-inflammatory cytokines. In addition, our study reaffirms the previously reported dissociation between the severity of sialoadenitis and extent of salivary gland dysfunction in NOD mice 13 . Surprisingly, despite dramatic differences in the composition of gut microbiome between JAX and Taconic mice, and distinct kinetics of diabetes, both groups developed sialoadenitis.
The role of hyperglycemia in salivary gland dysfunction is well established. Many individuals with diabetes develop xerostomia 14 . The C57BL/6-Ins2 Akita/J (Akita) mice carry a mutation in Ins2 (insulin 2 gene) and resemble juvenile-onset diabetes mellitus type I 15 . These mice are hyperglycemic without being autoimmune and they do not show any inflammatory cell infiltrates in their salivary glands. Yet they produce little or no pilocarpine-induced saliva, supporting a role for hyperglycemia in salivary gland dysfunction. Although precise mechanisms responsible for hyperglycemia-induced salivary gland dysfunction are not known, the localized production of ROS 16 and alterations in Ca2 + signaling in acinar cells has been proposed to cause functional changes in salivary glands 17 . In our study, serum levels of IL1β showed the most significant negative correlation (r = −0.7141, p < 0.0001) with saliva production. Furthermore, gene expression studies in salivary glands of hyperglycemic mice (Fig. 4 ) showed significant upregulation in the expression of Nfkbia (p = 0.0129) and Irak2 (p = 0.0487), which are associated with the IL1R signaling pathway.
A previous study in the NOD mice has demonstrated the role of IFNγ in salivary gland disease 18 . NOD mice lacking either IFNγ or its receptor (IFNγR) were protected from autoimmune responses targeting the salivary glands. In our study, the importance of IFNγ in salivary gland dysfunction is highlighted in normoglycemic mice, where serum IFNγ levels showed significant negative correlation with saliva amount (r = −0.7366, p = 0.0097) (see Supplemental Fig. S5 ). However, IL10, an anti-inflammatory cytokine also showed similar negative correlation with saliva amounts (r = −0.8082, p = 0.0037). It should be noted that even in normoglycemic mice, saliva amount shows significant inverse correlation with blood sugar (r = −0.636, p = 0.035). Collectively these data suggest that direct effects of high blood glucose and cytokines on salivary glands might be the contributing factors for glandular dysfunction in NOD mice. A recent study presented evidence for metabolic disorder in SS 19 . However, whether hyperglycemia contributes to SS pathogenesis can only be evaluated by monitoring SS patients for blood glucose levels.
The NOD mouse has been extensively used to test different therapeutic modalities for SS [5] [6] [7] [8] [9] [10] [11] . In many instances, treatments are initiated before the development of hyperglycemia. Whether the beneficial effects on SS phenotype were occurring through the regulation of diabetes has been investigated only in a few studies 10, 11 and . Gene expression analysis in submandibular glands of Taconic mice that were either hyperglycemic (n = 6) or normoglycemic (n = 6). RNA isolated from submandibular glands of mice euthanized at 20-24 wks of age was used for expression analysis. The nCounter mouse Immunology panel (NanoString Technologies, Seattle, WA, USA) was used to analyze the expression of 561 genes. Differential expression analysis was performed by using the nSolver Analysis software (NanoString Technologies, Seattle, WA, USA). Benjamini-Yekutieli False Discovery Rate method was used to calculate the adjusted p values. Please note only 3 genes Nfkbia, Irak2, and C4a showed significant differential expression. www.nature.com/scientificreports www.nature.com/scientificreports/ remains a critical factor for debate. In this context, a study reporting beneficial effects of resveratrol on SS phenotype suggested that high blood sugar was not a factor for glandular dysfunction in NOD mice 10 . In this report, at 22 weeks, only 2 out of 10 NOD mice had developed hyperglycemia, and these two hyperglycemic mice were among the lowest saliva producers. Of the 8 normoglycemic mice, only one mouse showed lower saliva production. Thus, the conclusion of a lack of correlation between saliva secretion and blood sugar in this report was not supported by robust data.
Considering these caveats in literature and the data presented in this manuscript, the mechanisms for glandular dysfunction in the NOD mouse, might not accurately represent mechanisms operative in SS patients. Thus, preclinical studies employing NOD mice, particularly for restoration of glandular function, need to be rigorously evaluated before any human clinical trials are undertaken. However, it should be noted that the NOD mouse model has provided valuable information on pathways involved in immune cell infiltration in the salivary glands and has utility to investigate mechanisms involved in this process 6, [20] [21] [22] . Based on our findings, we would like to suggest that the use of genetically modified NOD mice, which show critical characteristics of SS without developing hyperglycemia 23, 24 , is a valuable alternative for preclinical studies in SS.
